Rebound pathway overactivation by cancer cells following discontinuation of PI3K or mTOR inhibition promotes cancer cell growth. by Faes, S. et al.
  
 
Serveur Acade´mique Lausannois SERVAL serval.unil.ch
Author Manuscript
Faculty of Biology and Medicine Publication
This paper has been peer-reviewed but does not include the final publisher
proof-corrections or journal pagination.
Published in final edited form as:
Title: Rebound pathway overactivation by cancer cells following
discontinuation of PI3K or mTOR inhibition promotes cancer cell growth.
Authors: Faes S, Santoro T, Troquier L, De Souza Silva O, Dormond O
Journal: Biochemical and biophysical research communications
Year: 2019 Jun 4
Issue: 513
Volume: 3
Pages: 546-552
DOI: 10.1016/j.bbrc.2019.04.044
Rebound pathway overactivation by cancer cells following discontinuation of 
PI3K or mTOR inhibition promotes cancer cell growth 
Seraina Faes a, Tania Santoro a, 1, Laetitia Troquier a, Olga De Souza Silva a, Olivier 
Dormond a, * 
a Department of Visceral Surgery, Lausanne University Hospital, University of 
Lausanne, Pavillon 4, Av de Beaumont, 1011 Lausanne, Switzerland 
1 Present address: Department of Medicine, Lausanne University Hospital, University 
of Lausanne, Rue du Bugnon 46, 1011 Lausanne, Switzerland 
* Corresponding Author: Department of Visceral Surgery, Lausanne University
Hospital, University of Lausanne, Pavillon 4, Av de Beaumont, 1011 Lausanne, 
Switzerland. E-mail address: olivier.dormond@chuv.ch tel: ++41 79 556 03 40 
seraina.faes@chuv.ch, tania.santoro@chuv.ch, laetitia.troquier@chuv.ch, olga.de-
souza-silva@chuv.ch, olivier.dormond@chuv.ch 
Summary 
Whilst effects of anti-cancer drugs have been thoroughly explored, little is known about 
the repercussion of drug cessation. However, this has important clinical relevance 
since several clinical protocols such as intermittent drug scheduling lead to frequent 
drug discontinuation. In this study, we have thus investigated the consequences of 
withdrawal of agents that target the PI3K/AKT/mTOR signaling pathway in cancer 
cells. We report that washout of kinase inhibitors of mTOR or PI3K inhibitors led to a 
rapid and sustainable overactivation of AKT. Consequently, proliferation of tumor cells 
was significantly higher following drug washout in cancer cells that were pre-treated 
with mTOR or PI3K inhibitors compared to untreated cells. This effect was prevented 
by the addition of an AKT inhibitor following drug washout. Rebound AKT 
overactivation induced by mTOR or PI3K inhibitors discontinuation was mediated by 
IGF-1R, as demonstrated by its prevention in the presence of an IGF-1R inhibitor and 
by increased IGF-1R phosphorylation in treated cells versus control cells. Taken 
together, our results show that discontinuation of PI3K or mTOR inhibitors results in 
AKT overactivation that promotes tumor growth. They further highlight the benefit of 
adding an AKT inhibitor following cessation of PI3K or mTOR inhibitors. 
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1. Introduction 
Blocking activated proteins that partake in cancer progression represents a 
treatment modality in cancer therapy [1]. In this context, the inhibition of the 
PI3K/AKT/mTOR signaling pathway represents a promising approach as it contributes 
to tumor progression and its components are frequently overactivated in cancer cells 
[2-4]. Accordingly, numerous chemical inhibitors targeting different elements of the 
pathway have been developed [5]. However, despite promising pre-clinical 
observations, their anti-cancer benefits in patients are limited. In fact, the inhibition of 
the PI3K/AKT/mTOR pathway is associated with several drawbacks. For instance, 
inhibition of PI3K or AKT upregulates the expression and activity of multiple receptor 
tyrosine kinases that attenuate the anti-cancer efficacy of PI3K or AKT inhibitors [6-8]. 
Similarly, inhibition of mTORC1 abrogates negative feedback loops resulting in the 
activation of ERK and AKT [9, 10]. Therefore, the cellular consequences of the 
inhibition of the PI3K/AKT/mTOR signaling pathway are complex and need to be 
explicitly identified in order to design adequate therapeutic strategies [11]. 
In the field of cancer therapy, most studies have analyzed the effects of 
targeted therapies in the presence of specific inhibitors. In contrast, little is known 
about the repercussion of drug withdrawal. This aspect has however important clinical 
consequences as several protocols are exploring intermittent drug scheduling, in part 
to avoid substantial toxicities generated by such therapies [12-15]. In addition, the use 
of oral anti-cancer drugs is increasing, resulting in self-administered treatments [16]. 
Hence, decreased therapy adherence could contribute to drug cessation. This 
represents a particular issue as adherence rates of less than 20% have been reported 
in cancer patients [17]. 
In this study, we have investigated the consequences of withdrawal of mTOR 
or PI3K inhibitors in cancer cells. We report that drug washout resulted in a rapid 
overactivation of AKT promoting cancer cell growth. 
 
 
2. Materials and methods 
 
 
2.1. Reagents and antibodies 
 
 
PP242 (#CD0258), Ku-0063794 (#CD0274), and PX-866 (#CD0279) were 
from Chemdea (Ridgewood, NJ, USA). BKM-120 (#S2247), BYL719 (#S2814), MK-
2206 (#S1078), NVP-AEW541 (#S1034), sapitinib (#S2192), and erlotinib (#S7786) 
were from Selleck Chemicals (Houston, TX, USA). Anti-phospho-AKT (#4060), anti-
AKT (#2920), and anti phospho-IGF-1Rβ (#3024) antibodies were from Cell Signaling 
Technology (Danvers, MA, USA). Anti-β-Actin (#A2228) antibody was from Sigma-
Aldrich (Buchs, Switzerland). 
 
2.2. Cell culture 
 
 
SW480, HT-29, LS174T, 786-O, and Huh-7 cells were cultured in Dulbecco’s 
Modified Eagle’s Medium-high glucose (DMEM) (Sigma-Aldrich, Buchs, Switzerland) 
supplemented with 10% FBS and 1% streptomycin/penicillin in a 5% CO2 atmosphere 
and at 37ºC. 
 
2.2. MTS proliferation assay 
 
 
Cancer cells were plated in 96 well plates at 10 000 cells per well. Twenty-four 
hours later cells were treated with PP242 (5µM) or BKM-120 (500nM) or DMSO as a 
control for six hours. Drugs were washed out by rinsing cells four times with PBS and 
cells were subsequently incubated for 48 hours in DMEM/10% FBS. For some 
experiments, cancer cells were treated with MK-2206 (1µM) or NVP-AEW541 (1µM) 
after drug washout. Cellular proliferation was monitored after 48 hours with CellTiter 
96® AQueous One Solution Cell Proliferation Assay (MTS) (Promega, Madison, WI, 
USA) by following the manufacturer’s instructions. Absorbance at 492nm was 
measured 30 minutes after compound addition and expressed as a relative percentage 
compared to untreated control cells. Experiments were performed in triplicates and 
repeated three times. 
 
2.3. Cell counting 
 
 
Two hundred thousand cancer cells were plated in six well plates. Twenty-four 
hours later cells were treated with PP242 (5µM) or BKM-120 (500nM) or DMSO as a 
control for six hours. Drugs were washed out by rinsing cells four times with PBS and 
cells were subsequently incubated for 48 hours in DMEM/10% FBS. Subsequently, 
adherent cells were collected and trypan-blue negative cells were counted using a 
Neubauer hemocytometer. Results are expressed as relative mean cell count of three 
independent experiments compared to untreated control cells.  
 
2.4 Western blot analysis 
 
 
Two hundred thousand cancer cells were grown in six well plates and treated 
as indicated. Cells were washed twice with ice-cold PBS and lysed in RIPA buffer 
containing sodium orthovanadate and protease inhibitor cocktail (Santa Cruz 
Biotechnologies, Dallas, TX, USA). Protein concentrations were evaluated in lysates 
using BCA assay (Thermo Fischer Scientific, Waltham, MA, USA). Twenty micrograms 
of proteins per condition were separated on 4-12% polyacrylamide gels (Invitrogen, 
Waltham, MA, USA) and transferred to a polyvinylidene difluoride membrane. Odyssey 
blocking buffer (LI-COR Biosciences, Lincoln, NE, USA) was used to block 
membranes and, following incubation with primary and infrared secondary antibodies, 
bands from immunoreactive proteins were visualized by an Odyssey infrared imaging 
system. For some experiments densitometric analysis was performed using ImageJ 
software. Density values of phosphorylated proteins were normalized to total protein 
for each sample. Unstimulated cells were given a value of 1.0, and ratios in all other 
samples were normalized to this value. 
 
2.5. Statistical analysis 
 
Student’s t-tests were performed using GraphPad Prism version 8. p < 0.05 
was considered statistically significant. 
 
 
 
3. Results 
 
 
3.1. mTOR inhibitors or PI3K inhibitors washout in cancer cells increases AKT activity 
 
Whereas the effect of ATP-competitive inhibitors of mTOR on cancer cells has 
been thoroughly explored, little is known about the cellular consequences of drug 
cessation. To address this, SW480 or HT-29 colon cancer cells were treated with 5µM 
of PP242 [18] or 5µM of Ku-0063794 [19] for 24 hours followed by a drug washout of 
one hour. As expected, PP242 and Ku-0063794 inhibited mTORC2 activity as 
assessed by a decreased AKT phosphorylation of the serine 473 site [20]. Following 
one hour of drug washout, AKT (Ser 473) phosphorylation was however increased in 
cancer cells that were initially treated with PP242 or Ku-0063794 (Fig. 1A). Increased 
AKT phosphorylation following washout of mTOR inhibitors was not restricted to 
SW480 and HT-29 cancer cells as similar findings were obtained in Huh-7 
hepatocellular carcinoma cells and 786-O renal carcinoma cancer cells (Fig. 1B). The 
washout effect was also long lasting as we could still observe increased AKT 
phosphorylation 48 hours after drug withdrawal (Fig. 1C). Short-term exposure to 
mTOR inhibitor was sufficient to increase AKT phosphorylation upon drug washout as 
this effect was already observed after 6 hours of pre-treatment (Fig. 1D). Finally, a 
similar rebound activation of AKT was observed upon drug withdrawal of PI3K 
inhibitors. Treatment of cancer cells with PX-866 (500nM) [21] and BKM-120 (500nM) 
[22], both pan class I PI3K inhibitors as well as BYL719 (10M) [23], a selective PI3K 
alpha inhibitor, resulted in reduced AKT phosphorylation (Fig. 1E). However, following 
one hour of drug washout, AKT phosphorylation was increased in cancer cells 
previously treated with PI3K inhibitors. Taken together, these results show that 
withdrawal of PI3K or mTOR inhibitors leads to increased activation of AKT. 
 
3.2. mTOR or PI3K inhibitors washout promotes cancer cell growth 
 
Since AKT promotes cell proliferation and survival, we next hypothesized that 
increased AKT activity following drug washout would increase cell proliferation. To test 
this SW480, HT-29, 786-O, and Huh-7 were treated with PP242 or BKM-120 for six 
hours. Drugs were washed out and cell proliferation was assessed 48 hours later using 
MTS proliferation assay or cell counting (Fig. 2A). We found that washout of PP-242 
increased cell proliferation by 31.5%, 34.6%, 30.7%, and 32.6% in SW480, HT-29, 
786-O, and Huh-7 respectively compared to DMSO treated cells (Fig. 2B). Cell 
proliferation was upregulated by 40.9% in SW480 cells, 39.3% in HT-29 cells, 39,5% 
in 786-O cells, and 38.3% in Huh-7 cells following BKM-120 discontinuation compared 
to DMSO treated cancer cells (Fig. 2B). Similar results were obtained by cell counting 
(Fig. 2C). These results suggest that interruption of PI3K or mTOR inhibitors promotes 
cancer cell proliferation. 
 
3.3. AKT inhibitor MK-2206 blocks drug washout-mediated cancer cell growth 
 
To address the role of AKT in increasing cancer cell growth following 
withdrawal of PP242 or BKM-120, cancer cells were treated with AKT inhibitor MK-
2206 [24] following drug washout, and cell proliferation was monitored after 48 hours. 
We observed that as in Fig. 2 discontinuation of PP242 or BKM-120 increased cell 
proliferation compared to control cells treated with DMSO. We further found that in 
presence of MK-2206 proliferation of DMSO control cells was reduced by 46% in 
SW480 and 786-O cells, by 38% in HT-29 cells and by 47% in Huh-7 cells (Fig. 3). In 
addition, MK-2206 prevented upregulation of cell proliferation induced by cessation of 
PP242 or BKM120. This suggests that overactivation of AKT following PP242 or BKM-
120 discontinuation promotes cancer cell proliferation. 
 
3.4. Inhibition of IGF-1R precludes drug washout-mediated cancer cell growth 
 
Inhibition of AKT pathway leads to upregulation of receptor tyrosine kinases 
activities such as IGF-1R, insulin receptor, or HER3 [6]. Similarly, we found that 
washout of mTOR or PI3K inhibitors resulted in increased phosphorylation of IGF-1Rβ 
compared to control cells treated with DMSO (Fig. 4A). Inhibition of IGF-1R with NVP-
AEW541 [25] prevented AKT overactivation following washout of PP242 or BKM-120 
(Fig. 4B). In contrast, EGFR inhibitor erlotinib [26] or EGFR, Erb2, Erb3 inhibitor 
sapitinib [27] had no effect (Fig. 4B). Finally, increased cancer cell proliferation 
mediated by cessation of  PP242 or BKM-120 was prevented by NVP-AEW541 (Fig. 
4C). Taken together these results suggest that increased activity of IGF-1R following 
withdrawal of PP242 or BKM-120 upregulates cancer cell proliferation. 
 
4. Discussion 
 
Targeting the PI3K/AKT/mTOR signaling pathway in cancer has been less 
successful than expected. Limitations include activation of alternate proliferative 
signaling pathways due to abrogation of negative feedback loops following AKT or 
mTORC1 inhibition [6-10, 28]. In addition, transient inhibition of the pathway was 
documented. For instance, PI3K inhibitors block AKT activity with a progressive return 
to baseline after 48 hours due to PI3K independent activation mechanisms of AKT [29, 
30]. Here, we further report that discontinuation of PI3K or mTOR inhibitors leads to 
AKT overactivation that promotes cancer cell proliferation (Fig. 2). Consistent with our 
observation, a proliferative rebound was noted following discontinuation of the PI3K 
inhibitor GDC-0941 and recovery of PI3K activity in mice bearing tumors [15]. Whereas 
an association between increased cancer cell proliferation and tumor growth was not 
tested in this study, another study showed increased cancer growth following cessation 
of the dual PI3K/mTOR inhibitor NVP-BEZ235 [31], suggesting that drug withdrawal 
promotes a more aggressive phenotype.  
In HT-29 cells, upregulation of IGF-1R activity following drug withdrawal was 
responsible for signal transmission to AKT and stimulation of cancer cell proliferation 
(Fig. 4). Upregulation of the activity of growth factor receptors, not restricted to IGF-
1R, has been demonstrated following inhibition of the PI3K/AKT/mTOR signaling 
pathway. For instance, inhibition of AKT leads to FOXO dependent transcription of 
growth factor receptors including HER3, IGF-1R, and IR [6]. Similarly, suppression of 
PI3K leads to increased HER2/HER3 signaling that counteracts the anti-cancer 
efficacy of PI3K inhibitors [7, 8]. Consequently, combining growth factor receptors 
inhibitors with PI3K or mTOR inhibitors or combining PI3K or mTOR inhibitors with 
AKT inhibitors provide stronger anti-cancer efficacy than monotherapies. Our data 
further suggest that upregulation of growth factor receptors signaling persists after 
discontinuation of mTOR and PI3K inhibitors and recovery of AKT activity, resulting in 
increased cancer cell proliferation. Accordingly, inhibition of growth factor receptors 
and of AKT should be performed following discontinuation of PI3K or mTOR inhibitors 
to prevent rebound cancer cell proliferation. 
Several targeted therapies including PI3K and mTOR inhibitors are associated 
with significant toxicities upon continuous administration to patients [32]. Hence, new 
scheduling alternatives such as intermittent treatments need to be explored to limit 
these toxicities. In fact, transient pathway inhibition for example in the case of lapatinib 
has demonstrated similar anti-tumor response as continuous inhibition [13]. Similarly, 
intermittent BCR-ABL inhibition with dasatinib achieves clinical remission in chronic 
myeloid leukemia patients [12]. Intermittent treatment with PI3K and mTOR inhibitors 
should however be carefully monitored as our results suggest that AKT overactivation 
following drug withdrawal promotes cancer cell growth. 
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Figure Legends 
Fig. 1. mTOR inhibitors or PI3K inhibitors washout increases AKT phosphorylation (A) 
SW480 and HT-29 colon cancer cells were treated for 24 hours with 5µM of PP242 
(PP) or 5µM Ku-0063794 (Ku). Cell lysates were collected immediately or after one 
hour of drug washout and analyzed by immunoblotting for AKT and phospho-AKT (Ser 
473). Three independent experiments were quantified by densitometry and relative 
phospho-AKT levels are depicted. * p < 0.05. (B) Huh-7 and 786-O were processed 
as under panel (A) and cell lysates were analyzed by immunoblotting for AKT and 
phospho-AKT (Ser 473). (C) HT-29 colon cancer cells were treated for 24 hours with 
PP242 (5µM) or DMSO as a control. Drug was then washed out and cell lysates were 
collected 0, 1, 6, 12, 24, 48, and 72 hours after washout and analyzed by 
immunoblotting for AKT and phospho-AKT (Ser 473). (D) HT-29 cancer cells were 
treated with 5µM of PP242 for 1, 6, or 24 hours and subjected or not to one hour drug 
washout. Cell lysates were collected and analyzed for AKT and phospho-AKT (Ser 
473). (E) LS-174T colon cancer cells were treated for 24 hours with 500nM of BKM-
120 (BKM), 500nM of PX-866 (PX) or 10µM of BYL719 (BYL). Cell lysates were 
collected immediately or after one hour of drug washout and analyzed by 
immunoblotting for phospho-AKT (Ser 473) and actin. 
Fig. 2. Washout of mTOR or PI3K inhibitors promotes cancer cell growth. (A) 
Experimental design. SW480, HT-29, 786-O, or Huh-7 cancer cells were plated and 
treated 24 hours later with PP242 (5µM) or BKM-120 (500nM) for six hours. Drug 
washout was subsequently performed, and MTS proliferation assay or cell counting 
were performed after a further 48 hours. (B) MTS proliferation assay 48 hours post 
drug washout. Columns: Mean cell proliferation of three independent experiments 
expressed as percentage of DMSO treated cancer cells. Bars: SD. White columns: 
DMSO treated cells, grey columns: cell treated with PP242, and black columns: cells 
treated with BKM-120. * p < 0.05 compared to control cells. (C) Cell counting 48 hours 
post drug washout. Columns: Mean cell count expressed as percentage of DMSO 
treated cancer cells of three independent experiments. Bars: SD. * p < 0.05 compared 
to control cells. 
Fig. 3. Targeting AKT blocks drug washout mediated cancer cell growth. SW480, HT-
29, 786-O or Huh-7 were treated with DMSO, PP242 (5µM) or BKM-120 (500nM) for 
six hours. Drugs were washed out and cells were incubated with DMSO or MK-2206 
(1µM) for 48 hours before performing an MTS proliferation assay. Columns: Mean cell 
proliferation of three independent experiments expressed as percentage of DMSO 
treated cancer cells. Bars: SD. White columns: DMSO treated cells, grey columns: cell 
treated with PP242, and black columns: cells treated with BKM-120. * p < 0.05 
compared to control cells. 
Fig. 4. Blocking IGF-1R prevents drug washout mediated cancer cell growth. (A) 
Washout of PI3K or mTOR inhibitors increases IGF-1Rβ phosphorylation. HT-29 cells 
were treated for six hours with DMSO, BYL719 (10µM) (BYL), BKM-120 (500nM) 
(BKM), PP242 (5µM) or Ku0063794 (5µM) (Ku). Following washout, cells were 
incubated for six hours, and cell lysates were collected and analyzed for IGF-1Rβ 
phosphorylation and actin. (B) IGF-1R inhibition with NVP-AEW541 blocks AKT 
phosphorylation mediated by washout of PP242 or BKM-120. HT-29 cells were treated 
with DMSO, PP242 (5µM) or BKM-120 (500mM) for 6 hours. Following drug washout, 
cells were treated as indicated with sapitinib (2µM), NVP-AEW541 (1µM) (NVP-AEW) 
or erlotinib (1µM) for six hours, and AKT phosphorylation was assessed by Western 
blot in cell lysates. (C) NVP-AEW541 inhibits cancer cell proliferation induced by 
washout of PP242 or BKM-120. HT-29 cells were treated with DMSO, PP242 (5µM) 
or BKM-120 (500nM) for six hours. Following drug washout, cells were incubated with 
DMSO or NVP-AEW541 (1µM) for an additional 48 hours. Cell proliferation was 
assessed with an MTS proliferation assay. Columns: Mean cell proliferation of three 
independent experiments expressed as percentage of DMSO treated cancer cells. 
Bars: SD. White columns: DMSO treated cells, grey columns: cells treated with PP242, 
and black columns: cells treated with BKM-120. * p < 0.05 compared to control cells. 
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 Discontinuation of PI3K or mTOR inhibitors induces AKT overactivation.  
 Increased AKT activity following drug washout promotes cancer cell growth. 
 Targeting AKT following cessation of mTOR or PI3K inhibitors provides anti-cancer 
benefits. 
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